Nanosyrinx Ltd
NanoSyrinx is a discovery stage synthetic biology company developing a next-generation platform technology for targeted intracellular delivery of biological molecules. Their mission is to unlock the interior of the cell and the therapeutic opportunities within, by enabling targeted, intracellular delivery of protein therapeutics using a novel 'Nanosyringe' platform. The company was founded in 2020 and is backed by prominent investors including Octopus Ventures, BGF, MVentures, Eli Lilly and Company, IQ Capital, Meltwind, Pioneer Group, and UKI2S. NanoSyrinx aims to create a revolution in biologic drug delivery, addressing the challenge of delivering therapeutics into cells effectively and specifically.
Industries
Nr. of Employees
small (1-50)
Products
Protein-based intracellular delivery platform
A synthetic-biology derived platform designed to transport peptide and protein payloads into the cytosol of target cells, enabling access to intracellular targets that are otherwise difficult to drug.
Protein-based intracellular delivery platform
A synthetic-biology derived platform designed to transport peptide and protein payloads into the cytosol of target cells, enabling access to intracellular targets that are otherwise difficult to drug.
Services
Translational biology and preclinical study delivery
Design and execution of in vitro assays, ex vivo cell engineering workflows and in vivo proof-of-concept studies to validate delivery candidates and support target selection.
Process development and GMP-compatible bioprocessing
Development of scalable microbial fermentation and upstream manufacturing processes with a focus on GMP compatibility and regulatory readiness.
Candidate discovery and pipeline generation
Early-stage discovery workflows to identify and prioritise biologic delivery candidates for preclinical development.
Partnership facilitation and accelerator engagement
Provision of collaborative engagement with industry partners, accelerator programmes and access to shared laboratory infrastructure and mentorship.
Translational biology and preclinical study delivery
Design and execution of in vitro assays, ex vivo cell engineering workflows and in vivo proof-of-concept studies to validate delivery candidates and support target selection.
Process development and GMP-compatible bioprocessing
Development of scalable microbial fermentation and upstream manufacturing processes with a focus on GMP compatibility and regulatory readiness.
Candidate discovery and pipeline generation
Early-stage discovery workflows to identify and prioritise biologic delivery candidates for preclinical development.
Partnership facilitation and accelerator engagement
Provision of collaborative engagement with industry partners, accelerator programmes and access to shared laboratory infrastructure and mentorship.
Expertise Areas
- Intracellular delivery of biologic therapeutics
- Synthetic biology platform development
- Protein engineering for delivery
- Preclinical translational biology
Key Technologies
- Synthetic biology
- Protein engineering
- Non-viral intracellular delivery
- Microbial fermentation scale-up